VIR-2218 and peginterferon alfa-2a

Phase 2Small molecule

NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

VIR-2218 and peginterferon alfa-2a is one of 10 small molecule programs targeting Chronic Hepatitis b. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Hepatitis BActive, not recruiting

Chronic Hepatitis BPhase 2

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Chronic Hepatitis B

#DrugCompanyPhaseTrials

PEG-IFNα

Gilead

Phase 3

4 2

Hepatitis B Vaccine

Sanofi

Phase 2

1 3

Anti-PD-1 Antibody

Boehringer Ingelheim

Phase 2

2 4

AHB-137

AAusper Biopharma Co., Ltd.

Phase 2

7 5

Nas

AAusper Biopharma Co., Ltd.

Phase 2

4 6

Anti-PD-L1 Antibody

LLee's Pharmaceutical Limited

Phase 3

1 7

NA Therapy

GSK

Phase 2

1 8

GST-HG141

FFujian Akeylink Biotechnology Co., Ltd.

Phase 2

1 9

GST-HG131

FFujian Akeylink Biotechnology Co., Ltd.

Phase 2

1 10

VIR-2218 and peginterferon alfa-2a

NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Active, not recruiting

Chronic Hepatitis B

NCT06092333

Clinical

Trials by Indication[1]

Chronic Hepatitis b1 trial

A Pilot Study of the Combination of VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

Active, not recruiting·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT06092333·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VIR-2218 and peginterferon alfa-2a. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VIR-2218 and peginterferon alfa-2a compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VIR-2218 and peginterferon alfa-2a. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

VIR-2218 and peginterferon alfa-2a

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Chronic Hepatitis b1 trial

References

Drug Info

Quick Facts

Related News